ICML 2023 | Pembrolizumab monotherapy for older/ABVD-ineligible patients with Hodgkin lymphoma
Currently, there is no standard of care for older patients who develop classical Hodgkin lymphoma (cHL), and conventional chemotherapy is associated with several toxicities. In this video, Michael Dickinson, MBBS, DMedSc, FRACP, FRACPA, Peter MacCallum Cancer Centre, Melbourne, Australia, shares some insights into a study evaluating the safety and efficacy of pembrolizumab monotherapy in patients with cHL ineligible for frontline ABVD. Prof. Dickinson discusses the inclusion criteria for this trial, and further summarizes the results, including the progression-free and overall survival (PFS; OS) rates observed. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria: Roche, AbbVie, GenMab, Novartis, Kite, Gilead, Bristol Myers Squibb
Research funding: Roche, Novartis, Gilead, Takeda
